Cargando…

Patient-Initiated Follow-Up in Ovarian Cancer

This study aimed to assess the feasibility of patient-initiated follow-up (PIFU) in combination with regular tumour marker monitoring as an alternative to conventional hospital follow-up for ovarian cancer survivors. Women who had recently completed treatment for ovarian cancer and had a raised pre-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luk, Hiu Mei, Ngu, Siew Fei, Lau, Lesley S. K., Tse, Ka Yu, Chu, Mandy M. Y., Kwok, Shuk Tak, Ngan, Hextan Y. S., Chan, Karen K. L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136438/ https://www.ncbi.nlm.nih.gov/pubmed/37185389 http://dx.doi.org/10.3390/curroncol30040276

Ejemplares similares

Tamoxifen use in recurrent ovarian cancer in a Chinese population: A 15 ‐year clinical experience in a tertiary referral center
por: Chan, Karen Kar Loen, et al.
Publicado: (2020)

A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy: a case report
por: Ngu, Siew-Fei, et al.
Publicado: (2022)

Diagnostic Performance of Risk of Malignancy Algorithm (ROMA), Risk of Malignancy Index (RMI) and Expert Ultrasound Assessment in a Pelvic Mass Classified as Inconclusive by International Ovarian Tumour Analysis (IOTA) Simple Rules
por: Ngu, Siew Fei, et al.
Publicado: (2022)

Clinical performance of the Roche Cobas 4800 HPV test for primary cervical cancer screening in a Chinese population
por: Liu, Stephanie S., et al.
Publicado: (2022)

Surgery including fertility-sparing treatment of GTD
por: Ngu, Siew-Fei, et al.
Publicado: (2021)

Human Papillomavirus Self-Sampling for Primary Cervical Cancer Screening in Under-Screened Women in Hong Kong during the COVID-19 Pandemic
por: Ngu, Siew-Fei, et al.
Publicado: (2022)

Oncogenic microRNA signature for early diagnosis of cervical intraepithelial neoplasia and cancer
por: Liu, Stephanie S., et al.
Publicado: (2018)

Evaluation of an Isothermal Amplification HPV Assay on Self-Collected Vaginal Samples as Compared to Clinician-Collected Cervical Samples
por: Chan, Aaron H. Y., et al.
Publicado: (2023)

Association between High Diffusion-Weighted Imaging-Derived Functional Tumor Burden of Peritoneal Carcinomatosis and Overall Survival in Patients with Advanced Ovarian Carcinoma
por: An, He, et al.
Publicado: (2022)

PDK1 promotes ovarian cancer metastasis by modulating tumor-mesothelial adhesion, invasion, and angiogenesis via α5β1 integrin and JNK/IL-8 signaling
por: Siu, Michelle K. Y., et al.
Publicado: (2020)

The Value of Four-Quadrant Cervical Biopsy in Women with Different Colposcopic Impressions
por: Chu, Mandy Man-Yee, et al.
Publicado: (2023)

Applications and Safety of Sentinel Lymph Node Biopsy in Endometrial Cancer
por: Chiu, Wan Kam, et al.
Publicado: (2022)

Molecular Biomarkers for the Early Detection of Ovarian Cancer
por: Zhang, Ruiqian, et al.
Publicado: (2022)

Aberrant Cholesterol Metabolism in Ovarian Cancer: Identification of Novel Therapeutic Targets
por: He, Jiangnan, et al.
Publicado: (2021)

New Insights into Ferroptosis Initiating Therapies (FIT) by Targeting the Rewired Lipid Metabolism in Ovarian Cancer Peritoneal Metastases
por: Zhan, Shijie, et al.
Publicado: (2022)

Tumour Suppressive Function and Modulation of Programmed Cell Death 4 (PDCD4) in Ovarian Cancer
por: Wei, Na, et al.
Publicado: (2012)

Targeting of lipid metabolism with a metabolic inhibitor cocktail eradicates peritoneal metastases in ovarian cancer cells
por: Chen, Rain R., et al.
Publicado: (2019)

Differentiation of aggressive and indolent subtypes of uterine sarcoma using maximum standardized uptake value
por: Lee, Elaine Yuen Phin, et al.
Publicado: (2013)

Metabolic active peritoneal sites affect tumor debulking in ovarian and peritoneal cancers
por: Tsoi, Tung Tung, et al.
Publicado: (2020)

Germline mutations in Chinese ovarian cancer with or without breast cancer
por: Kwong, Ava, et al.
Publicado: (2022)

Orchestrated Action of AMPK Activation and Combined VEGF/PD-1 Blockade with Lipid Metabolic Tunning as Multi-Target Therapeutics against Ovarian Cancers
por: Yung, Mingo M. H., et al.
Publicado: (2022)

GRO-α and IL-8 enhance ovarian cancer metastatic potential via the CXCR2-mediated TAK1/NFκB signaling cascade
por: Yung, Mingo Ming-Ho, et al.
Publicado: (2018)

Methylation-associated silencing of miR-193a-3p promotes ovarian cancer aggressiveness by targeting GRB7 and MAPK/ERK pathways
por: Chen, Kangmei, et al.
Publicado: (2018)

Germline PALB2 Mutation in High-Risk Chinese Breast and/or Ovarian Cancer Patients
por: Kwong, Ava, et al.
Publicado: (2021)

Estrogen receptor modulators genistein, daidzein and ERB-041 inhibit cell migration, invasion, proliferation and sphere formation via modulation of FAK and PI3K/AKT signaling in ovarian cancer
por: Chan, Karen K. L., et al.
Publicado: (2018)

The Stress-Inducible BCL2A1 Is Required for Ovarian Cancer Metastatic Progression in the Peritoneal Microenvironment
por: Liang, Rui, et al.
Publicado: (2021)

Increased Expression of PITX2 Transcription Factor Contributes to Ovarian Cancer Progression
por: Fung, Frederic K. C., et al.
Publicado: (2012)

Differential expression of estrogen receptor subtypes and variants in ovarian cancer: effects on cell invasion, proliferation and prognosis
por: Chan, Karen K. L., et al.
Publicado: (2017)

PFKFB3 Regulates Chemoresistance, Metastasis and Stemness via IAP Proteins and the NF-κB Signaling Pathway in Ovarian Cancer
por: Jiang, Yu-xin, et al.
Publicado: (2022)

Aberrant Activation of ERK/FOXM1 Signaling Cascade Triggers the Cell Migration/Invasion in Ovarian Cancer Cells
por: Lok, Gabriel T. M., et al.
Publicado: (2011)

Reduced expression of AMPK-β1 during tumor progression enhances the oncogenic capacity of advanced ovarian cancer
por: Li, Cuilan, et al.
Publicado: (2014)

Soluble E-cadherin promotes tumor angiogenesis and localizes to exosome surface
por: Tang, Maggie K. S., et al.
Publicado: (2018)

Correction: Reduced expression of AMPK-ß1 during tumor progression enhances the oncogenic capacity of advanced ovarian cancer
por: Li, Cuilan, et al.
Publicado: (2014)

Loss of Programmed cell death 4 (Pdcd4) associates with the progression of ovarian cancer
por: Wei, Na, et al.
Publicado: (2009)

Hexokinase 2 Regulates Ovarian Cancer Cell Migration, Invasion and Stemness via FAK/ERK1/2/MMP9/NANOG/SOX9 Signaling Cascades
por: Siu, Michelle K. Y., et al.
Publicado: (2019)

A comprehensive systematic review and network meta-analysis: the role of anti-angiogenic agents in advanced epithelial ovarian cancer
por: Helali, Aya El, et al.
Publicado: (2022)

TAp73-Mediated the Activation of C-Jun N-Terminal Kinase Enhances Cellular Chemosensitivity to Cisplatin in Ovarian Cancer Cells
por: Zhang, Pingde, et al.
Publicado: (2012)

Management of Chemoresistant and Quiescent Gestational Trophoblastic Disease
por: Ngu, Siew-Fei, et al.
Publicado: (2014)

Targeting GRB7/ERK/FOXM1 Signaling Pathway Impairs Aggressiveness of Ovarian Cancer Cells
por: Chan, David W., et al.
Publicado: (2012)

Elevated TAK1 augments tumor growth and metastatic capacities of ovarian cancer cells through activation of NF-κB signaling
por: Cai, Patty C.H., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qm1mqmqjs76oibr6r3r93bjk8c